Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 2/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5565867 | 0.99 | MAPK13 (0.44) | MAPK13MAPK12MAPK11MAPK14MEP1B | |
| SCHEMBL5565863 | 0.98 | MAPK13 (0.45) | MAPK13MAPK12MAPK11MAPK14MEP1B | |
| SCHEMBL5569066 | 0.91 | ALDH1A1 (0.49) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5568892 | 0.90 | ALDH1A1 (0.48) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5565105 | 0.89 | MAPK13 (0.48) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5569147 | 0.89 | MAPK13 (0.55) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5568923 | 0.89 | KAT6A (0.43) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5568715 | 0.88 | ALDH1A1 (0.47) | — | |
| SCHEMBL5564727 | 0.88 | KAT6A (0.42) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5564570 | 0.87 | ALDH1A1 (0.43) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480976-B1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-19 | — | — | EP | disclosed |
| EP-1480976-A1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| US-6686381-B2 | COMPOUNDS THAT ANTAGONIZE NEUROPEPTIDE Y AT THE Y5 RECEPTOR SUBTYPE REPRESENT AN APPROACH TO THE TREATMENT OF EATING DISORDERS SUCH AS OBESITY AND HYPERPHAGIA | HOFFMANN-LA ROCHE INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030225141-A1 | THIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003072577-A1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225141-A1 | THIAZOLE DERIVATIVES | SLC5A1, GPR119, TAS1R1 | MAPK13 3868/4885MAPK12 4156/4885MAPK11 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.